Company news

Larimar Therapeutics, Inc. news in 2024

Larimar Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia

December 15, 2024

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

October 29, 2024

Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research

September 18, 2024

Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results

August 6, 2024

Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia

May 29, 2024

Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia

May 19, 2024

Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results

May 8, 2024

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

March 13, 2024

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia

March 10, 2024

Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

February 13, 2024

Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia

February 11, 2024

Decks in 2024